Nuformix

    OverviewSuggest Edit

    Nuformix (formerly known as Levrett) is a company that develops pharmaceutical products. The Company uses cocrystal technology. Its products include NXP001 for oncology supportive care, NXP002 for use in the treatment of fibrosis, and NXP003.

    TypePublic
    Founded2008
    HQCambridge, GB
    Websitenuformix.com

    Latest Updates

    Employees (est.) (Dec 2017)1

    Key People/Management at Nuformix

    Daniel Gooding

    Daniel Gooding

    CEO
    Chris Blackwell

    Chris Blackwell

    Pharma Executive
    Show more

    Nuformix Office Locations

    Nuformix has an office in Cambridge
    Cambridge, GB (HQ)
    153 Cambridge Science Park Milton Road
    Show all (1)

    Nuformix Blogs

    Nuformix Commences NXP001 Clinical Trial

     Cambridge, UK, 22 March 2019: Nuformix (LSE: NFX), the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces it has commenced clinical studies for the Company’s lead asset NXP001. The post Nuformix Commences NXP…

    Nuformix Announces MHRA Approval to Commence NXP001 Human Pharmacokinetics Studies

    Nuformix (LSE: NFX), the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces it has received approval from the UK Medicines and Healthcare Products Regulatory Agency (“MHRA”) to commence human pharmacokinetics …

    Notification Major Share Interests

    Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces: TR-1: Standard form for notification of major holdings The post Notification Major Share Interests appeared first on Nuformix.

    Nuformix Announces Unaudited Half Year Results for the Period Ending 30 September 2018

    Nuformix (LSE: NFX), the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces the Company’s unaudited results for the six months ended 30 September 2018. The post Nuformix Announces Unaudited Half Year Results f…

    Nuformix Reports Results from Novel Pre-Clinical Trial in IPF for NXP002 Programme

    Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces results from the completion of its innovative pre-clinical trial for its NXP002 fibrosis programme in human idiopathic pulmonary fibrosis (‘IPF’…

    Nuformix Expands Licensing Agreement with Newsummit Biopharma for cancer supportive care product

    Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces it has expanded its licensing agreement with Newsummit Biopharma (“NSB”), its Chinese licensing partner for NXP001, which is in development for …
    Show more

    Nuformix Frequently Asked Questions

    • When was Nuformix founded?

      Nuformix was founded in 2008.

    • Who are Nuformix key executives?

      Nuformix's key executives are Daniel Gooding and Chris Blackwell.

    • How many employees does Nuformix have?

      Nuformix has 1 employees.

    • Who are Nuformix competitors?

      Competitors of Nuformix include Parexel International, Fate Therapeutics and Chiasma.

    • Where is Nuformix headquarters?

      Nuformix headquarters is located at 153 Cambridge Science Park Milton Road, Cambridge.

    • Where are Nuformix offices?

      Nuformix has an office in Cambridge.

    • How many offices does Nuformix have?

      Nuformix has 1 office.